DPI-289

DPI-289 is a novel, orally bioavailable small molecule designed as a bi-functional opioid modulator, acting as a **delta opioid receptor agonist** and a **mu opioid receptor antagonist** (DAMA). It is under development primarily for **Parkinson's disease**, targeting motor symptoms and aiming to reduce L-DOPA-induced dyskinesia and L-DOPA dose requirements. Preclinical studies in rodent and non-human primate models demonstrate antiparkinsonian efficacy without inducing dyskinesia, with DPI-289 enhancing the benefit of L-DOPA while potentially minimizing side effects seen with standard dopaminergic therapies. The compound is being developed by Eboo Pharmaceuticals, with key research conducted in collaboration with Atuka Inc. and Dina Pharmaceuticals[1][3][4][5].